Ann: Share Purchase Plan, page-23

I think as shareholders we deserve greater transparency and more info on the recent acquisition.

Eg, revenue of Danodan, growth numbers, projections and sales figures on their product line. None of which has been provided.

Essentially, Danodan, which is a $250k business (that’s what we’re paying - the rest of for a patent) has triggered a $2mill loss on market cap value and 25% dilution to shareholders as a result.

I want to understand better how Danodan is worth the short term pain and consequence to shareholders for long term gain.

I will certainly be asking these questions at the AGM and encourage others to do the same.